The News
Esmertec decides to postpone its IPO
05/07/2005
Duebendorf-Zurich, Switzerland – July 5, 2005 – Esmertec™, a leading global, independent developer of software solutions for mobile handsets and embedded devices, announced today that it is postponing its planned IPO.
As a result of the marketing effort conducted by management during the roadshow, investors exhibited very strong interest in Esmertec’s IPO. Nevertheless, following two press releases - one issued on July 1st about an alleged patent situation and the second on July 3rd regarding a customer placed into administration - the company believes that the conditions for the pricing and trading of the IPO are currently not optimal.
As a result, Esmertec and its Board of Directors, after consultation with UBS Investment Bank and Deutsche Bank as Joint Bookrunners, have decided to postpone the IPO.
The board, the management and the investors of Esmertec are confident about the current development and future prospects of the company based on Esmertec’s history and significant demonstrated growth.
About Esmertec
Esmertec is a leading provider of software solutions for mobile phones and embedded devices. Our high-performance solutions are delivered to chipset and embedded devices manufacturers in mobile and landline telecommunication, home-multimedia, machine-to-machine and consumer electronics markets. Engineered for smallness, Esmertec's wireless Java™ (Java ME) solutions, mobile applications and components, and object-oriented software platform (OSVM™) are designed to extract maximum performance from hardware environments. Founded in 1999, Esmertec is a global company headquartered in Zurich, with engineering, sales and customer support operations in Switzerland, China, Denmark, France, Japan, Korea, Singapore, Taiwan, the UK and the USA.
Contact
Leng Stricker-Wong
Phone +41 1 823 8954
lstricker@esmertec.com
This press release is not an offer of securities for sale in the United States. No securities may be offered or sold in the United States absent registration or an exemption from registration, and any public offer of securities to be made in the United States will be made by means of a prospectus that may be obtained from Esmertec AG. Such prospectus will contain detailed information about Esmertec and its management, as well as its financial statements. This press release is not being made and may not be distributed or sent into Australia, Canada or Japan.
This document is only directed at persons who: (i) are outside the United Kingdom; or (ii) have professional experience in matters relating to investments; or (iii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations etc”) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (all such persons being together referred to as “relevant persons”). This press release must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons.
The announcement is not an offer of securities under Swiss Law. It is not a listing prospectus according to art. 652a and/or art. 1156 Swiss Code of Obligations or art. 32 ff. Swiss Listing Rules and is not a listing notice according to art. 45 ff. Swiss Listing Rules.
"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995. The matters discussed in this press release include forward-looking statements that are subject to risks and uncertainties including, but not limited to the impact of changes in product demand, pricing and competition, including increased competition from existing or new competitors or new technologies and the risk that our software may contain defects; product development risks, including our ability to develop enhancements to our software or to develop new commercially viable technologies and our ability to protect our intellectual property rights and to defend them against infringement; a potential reversal of the trend among mobile handset manufacturers to outsource the development of Java solutions; the loss of key customers; managements ability to develop and execute a successful strategy, including partnerships, acquisitions, divestitures and ability to manage growth; adverse regulatory, legislative and judicial developments; our failure to retain key personnel; the adverse impact of currency exposures; and the impact of worldwide economic, political and business conditions.
Esmertec is a trademark of Esmertec AG. Java is a trademarks of Sun Microsystems, Inc. Other company, product and service names may be trademarks of their respective owners.
2005
- 03/01/2005
- 01/01/2005
- 05/01/2005
- 10/01/2005
- 17/01/2005
- 17/01/2005
- 19/01/2005
- 27/01/2005
-
27/01/2005
XYOTAXTM Pivotal Trial in Non-Small Cell Lung Cancer, STELLAR 3, Reaches Required Number of Events
-
28/01/2005
Esmertec and MontaVista Software to deliver integrated Java-Linux solutions for mobile phones
-
28/01/2005
Esmertec et MontaVista Software proposent des solutions Java-Linux intégrées pour terminaux Mobiles
- 02/02/2005
-
02/02/2005
Esmertec acquiert la Division Mobile de CoreTek Systems, en Chine
- 07/02/2005
- 07/02/2005
-
08/02/2005
XYOTAX Patent Allowance Provides Exclusivity in Europe Until 2017
-
08/02/2005
WebSideStory Announces Agreement to Acquire Atomz and Launch of Active Marketing Suite
-
16/02/2005
Important soutien financier en faveur des recherches sur le cancer de DIATOS N.V.
-
16/02/2005
DIATOS N.V.’s oncology research boosted by significant funding
- 22/02/2005
- 22/02/2005
- 08/03/2005
-
10/03/2005
Sofinnova Parners voted European VC Firm of the year in Global Private Equity Awards
-
10/03/2005
Sofinnova Parners voted European VC Firm of the year in Global Private Equity Awards
- 16/03/2005
-
16/03/2005
Varioptic to demonstrate the world's first liquid zoom lens for camera phones at Cebit
- 15/03/2005
- 17/03/2005
-
22/03/2005
CoTherix's Ventavis(R) Commercially Available for the Treatment of Pulmonary Arterial Hypertension
-
22/03/2005
CoTherix's Ventavis(R) Commercially Available for the Treatment of Pulmonary Arterial Hypertension
- 24/03/2005
-
24/03/2005
Nomination de Jean Schmitt comme Partenaire-Associé chez Sofinnova Partners
- 24/03/2005
- 24/03/2005
- 06/04/2005
- 06/04/2005
- 08/04/2005
- 08/04/2005
- 04/04/2005
-
12/04/2005
Neuro3d Reports Positive Results from Phase II Trials of Ocaperidone in Schizophrenia
-
12/04/2005
Diatos S.A. opens its US subsidiary in California - Diatos USA, Inc.
- 14/04/2005
-
26/04/2005
GPC Biotech and Ingenium Receive € 2.2 Million Joint Drug Discovery Grant from German Ministry
-
26/04/2005
GPC Biotech and Ingenium Receive € 2.2 Million Joint Drug Discovery Grant from German Ministry
- 12/05/2005
-
12/05/2005
6WIND announces R&D partnership with China academy of science
- 16/05/2005
- 16/05/2005
-
16/05/2005
New Ventavis(R) Data to Be Presented at American Thoracic Society's International Conference
-
16/05/2005
New Ventavis(R) Data to Be Presented at American Thoracic Society's International Conference
-
17/05/2005
DIATOS and SERVIER announce oncology research collaboration using the VECTOCELL® technology
-
17/05/2005
DIATOS and SERVIER announce oncology research collaboration using the VECTOCELL® technology
-
17/05/2005
DIATOS S.A. opens its US subsidiary in California – DIATOS USA, INC.
-
17/05/2005
DIATOS S.A. opens its US subsidiary in California – DIATOS USA, INC.
- 19/05/2005
- 23/05/2005
- 19/05/2005
- 23/05/2005
- 23/05/2005
- 23/05/2005
-
07/06/2005
OXXIUS Shrinks DPSS Lasers and announces world’s smallest blue laser module
-
07/06/2005
OXXIUS Shrinks DPSS Lasers and announces world’s smallest blue laser module
- 20/06/2005
-
20/06/2005
Sofinnova Partners investit 4 millions d'euros dans Endotis Pharma
- 14/06/2005
- 14/06/2005
-
27/06/2005
Esmertec et LG Electronics présentent un mobile doté d’une JVM (Java Virtual Machine) multi-tâches
-
27/06/2005
Esmertec and LG Electronics Demonstrate Multi-tasking Java Virtual Machine on a Mobile Handset
-
28/06/2005
Revolt technology receives €7 million in first round of financing
-
05/07/2005
Esmertec decides to postpone its IPO
- 08/07/2005
-
06/07/2005
Esmertec officially opened its R&D and Customer Support Center in Chengdu, China
- 28/07/2005
- 22/08/2005
-
16/08/2005
Epimmune and IDM S.A. Join Forces to become IDM Pharma, Inc.
-
16/08/2005
Epimmune et IDM S.A. fusionnent pour devenir IDM PHARMA, INC.
-
25/07/2005
UPEK® provides Biometric Finger security for the THINKPAD* Tablet
-
21/07/2005
InfraWorlds acquiert 995 SOFT et entre sur le marché américain
-
25/07/2005
Infraworlds crée un nouveau format de jeu grand public : SagaZ
- 25/07/2005
-
03/08/2005
Infraworlds creates SagaZ, a new game format for the mass market
- 26/07/2005
- 28/07/2005
- 22/08/2005
- 22/08/2005
- 30/08/2005
-
31/08/2005
NEC Infrontia fait de Jbed CDC, la plate-forme Java d’Esmertec, son standard JVM
- 31/08/2005
-
06/09/2005
Varioptic expands its focus to deliver liquid lenses in new markets
- 26/09/2005
-
30/09/2005
VoluBill announces “Charge it” – a comprehensive mobile data charging solution
- 03/10/2005
- 30/09/2005
-
05/10/2005
Sofinnova Partners annonces the successful stock market flotations of two portfolio companies
- 17/10/2005
- 25/10/2005
- 20/10/2005
- 07/11/2005
- 14/11/2005
- 10/11/2005
-
23/09/2005
Servista wins "BPO Service Provider of the Year" at NOA awards ceremony 2005
- 15/11/2005
-
22/11/2005
Tsinghua Tongfang and 6Wind partnership to take China's booming ICT market by storm
-
22/11/2005
Tsingha Tongfang et 6Wind à la conquête du marché chinois des TIC
-
17/11/2005
6Wind contributes to success of KDDI's mobile broadband project
-
17/11/2005
6Wind contribue au succès du projet de réseau mobile haut débit mené par l'opérateur japonnais KDDI
- 21/11/2005
-
21/11/2005
Howard Ford former Managing Director of Equant joins Varioptic as Chairman of the Board Lyon, France
- 19/10/2005
- 24/11/2005
- 06/12/2005
-
13/12/2005
CoTherix and Respironics Announce Launch of New Portable Inhalation Device to Ventavis Patients
- 13/12/2005
- 13/12/2005
-
14/12/2005
Professor Peter Van Brummelen and DR. Annick Schwebig join the board of directors of Diatos S.A.
- 29/11/2005
- 26/12/2005
- 23/12/2005